Amprenavir

立即咨询

Amprenavir

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	161814-49-9
规格:	≥98%

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
25mg	电议
50mg	电议
100mg	电议
250mg	电议
500mg	电议

产品介绍

Amprenavir (formerly VX-478; trade name Agenerase and Prozei), an FDA approved drug for treating HIV infections, is a potent PXR-selective agonist, and an HIV protease inhibitor with the IC50 of 0.6 nM on HIV-1 protease, it also weakly inhibits HIV-2 protease with IC50 value of 19 nM. In addition, it is reported to be a Cytochrome P450 3A4 Inhibitor. Amprenavir has been effectively used for the treatment of HIV disease in patients with primary HIV infection. It was approved by the FDA on April 15, 1999, for twice-a-day dosing instead of needing to be taken every eight hours.

理化性质和储存条件

Molecular Weight (MW)	505.63
Formula	C25H35N3O6S
CAS No.	161814-49-9 (Amprenavir);
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 100 mg/mL (197.8 mM)
	Water: <1 mg/mL
	Ethanol: 16 mg/mL (31.6 mM)
Other info	Chemical Name: [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate InChi Key: YMARZQAQMVYCKC-UHFFFAOYSA-N InChi Code: InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30) SMILES Code: CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
Synonyms	141W94, VX-478, KVX-478; VX 478; VX478; Agenerase; Prozei; KVX 478; KVX478; Amprenavir;

实验参考方法

In Vitro	In vitro activity: Amprenavir promotes the specific interactions between the nuclear receptor pregnane X receptor (PXR) and the coactivators SRC-1 and PBP. Amprenavir is docked into the high-resolution crystal structure of human PXR in complex with SR12813. Amprenavir occupies all four subpockets, and its hydroxyl group forms a hydrogen bond with Ser247, which is located in the connection region of PXR, to help to position the drug in the optimal orientation inside the receptor. Amprenavir forms direct contacts with one residue on αAF of the PXR activation function-2 (AF-2) surface, Phe429, which may stabilize the active AF-2 conformation of the receptor and contribute to the agonist activity of amprenavir on PXR. Amprenavir induces the expression of bona fide PXR target genes involved in phase I (CYP3A4), phase II (UGT1A1), and phase III (MDR1) metabolism in both HepaRG cells and LS180 cells. Cell Assay: Amprenavir induced PXR target gene expression in both HepaRG hepatoma cells and LS180 intestinal cells.
In Vivo	Amprenavir increases atherogenic LDL cholesterol fractions in WT mice, but not in PXR–/– mice. Amprenavir stimulates expression of known PXR target genes, including CYP3A11, glutathione transferase A1, and MDR1a, in the intestine of WT mice but not in PXR–/– mice. Amprenavir-mediated PXR activation stimulates the expression of both LipF and LipA in the intestine of WT mice, but not in PXR–/– mice, indicating a possible role of intestinal PXR in mediating dietary lipid breakdown and absorption in mammals.
Animal model	WT and PXR-/- mice
Formulation & Dosage	10 mg/kg; p.o.
References	Mol Pharmacol. 2013 Jun;83(6):1190-9.

生物活性

		Amprenavir is a potent PXR-selective agonist. Mol Pharmacol. 2013 Jun;83(6):1190-9.
Key residues of PXR LBD are required for amprenavir’s agonistic activity. Mol Pharmacol. 2013 Jun;83(6):1190-9.	Amprenavir elicits hyperlipidemia in WT, but not in PXR–/– mice. Mol Pharmacol. 2013 Jun;83(6):1190-9.	Amprenavir elevates atherogenic LDL cholesterol levels in WT mice. Mol Pharmacol. 2013 Jun;83(6):1190-9.